PHARMACEUTICAL

三个皮匠报告为您整理了关于PHARMACEUTICAL的更多内容分享，帮助您更详细的了解PHARMACEUTICAL，内容包括PHARMACEUTICAL方面的资讯，以及PHARMACEUTICAL方面的互联网报告、券商研究报告、国际英文报告、公司年报、招股说明书、行业精选报告、白皮书等。

PHARMACEUTICALTag内容描述：

1、44thAnnualJ,P,MorganHealthcareConferenceJanuary14,2026IntroductionCorporateOverviewLifeCycleManagementofOPDIVOImpactofDe。

2、ESGReport2024TableofContentsCEOMessage32024ESGHighlights4ESGatCollegium5AboutCollegium6Governance11Social14Environment24。

3、UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549,Form10,K,MarkOne,ANNUALREPORTPURSUANTTOSECTION13OR15,d,O。

4、2023ANNUALINTEGRATEDREPORTFiscalYearendedMarch31,2023AboutTAKEDAISAGLOBALvalues,based,researchanddevelopment,RD,drivenbi。

5、04UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549FORM10,KANNUALREPORTPURSUANTTOSECTION13OR15,d,OFTHESECU。

6、TableofContents04UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549FORM10,KANNUALREPORTPURSUANTTOSECTION13O。

7、2022AnnualIntegratedReportFiscalYearEndedMarch31,2022Contents03CEOLettertoStakeholders05MessagefromtheE,ternalDirector,C。

8、AsfiledwiththeSecuritiesandE,changeCommissiononJune29,2021UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,2054。

9、TableofContents04UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549FORM10,KANNUALREPORTPURSUANTTOSECTION13O。

10、UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549,Form10,K,MarkOne,ANNUALREPORTPURSUANTTOSECTION13OR15,d,O。

11、AsfiledwiththeSecuritiesandE,changeCommissiononJune24,2020UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,2054。

12、TableofContents04UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549FORM10,KANNUALREPORTPURSUANTTOSECTION13O。

13、TableofContents04UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549FORM10,KANNUALREPORTPURSUANTTOSECTION13O。

14、AsfiledwiththeSecuritiesandE,changeCommissiononJune27,2019UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,2054。

15、UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,D,C,20549FORM10,K,ANNUALREPORTPURSUANTTOSECTION13OR15,d,OFTHESECUR。

16、TableofContents04UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549FORM10,KANNUALREPORTPURSUANTTOSECTION13O。

17、AsfiledwiththeSecuritiesandE,changeCommissiononDecember17,2018UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C。

18、UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,K,ANNUALREPORTPURSUANTTOSECTION13OR15,d,OFTHESECURIT。

19、CreatingvalueforpatientsaroundtheworldSustainableValueReport2017TakedaSustainableValueReport2017MessagefromthePresidentC。

20、TableofContents04UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549FORM10,KANNUALREPORTPURSUANTTOSECTION13O。

21、UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,K,ANNUALREPORTPURSUANTTOSECTION13OR15,d,OFTHESECURIT。

22、TableofContents04UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549FORM10,KANNUALREPORTPURSUANTTOSECTION13O。

23、MorningstarDocumentResearchFORM10,KBIOMARINPHARMACEUTICALINC,BMRNFiled,February27,2017,period,December31,2016,Annualrepo。

24、BetterHealth,BrighterFutureTakedaPharmaceuticalCompanyLimitedAnnualReport2016DetailedinformationonCorporateSocialRespons。

25、TableofContents04UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWashington,D,C,20549FORM10,KANNUALREPORTPURSUANTTOSECTION13O。

26、UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,K,ANNUALREPORTPURSUANTTOSECTION13OR15,d,OFTHESECURIT。

27、BIOMARINPHARMACEUTICALINCFORM10,K,AnnualReport,Filed022916forthePeriodEnding123115Address105DIGITALDRIVENOVATO,CA94949Te。

28、AnnualReport2015DetailedinformationonCorporateSocialResponsibility,CSR,CSRDataBookTakedaPharmaceuticalCompanyLimitedTake。

29、UNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,K,ANNUALREPORTPURSUANTTOSECTION13OR15,d,OFTHESECURIT。

30、Teva2014GlobalCitizenshipReportInnovatingforBetterHealthABOUTTEVATevaataglanceMessagefromourPresidentandCEO,ErezVigodman。

31、1CorporateSocialMeetingOurPatientsNeedsResponsibilityReport2TevaCSRCEOLetterALetterFromErezVigodman,TevasPresidentCEOThi。

32、MeetingPatientNeeds2012CorporateSocialResponsibilityReportaA6,AboutTevaOurpatientsOuremployeesOurcommunityOurenvironment。

33、TableofContentsUNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,K,ANNUALREPORTPURSUANTTOSECTION13OR15。

34、TableofContentsUNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,KANNUALREPORTPURSUANTTOSECTION13OR15。

35、TableofContentsUNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,KANNUALREPORTPURSUANTTOSECTION13OR15。

36、TableofContentsUNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,KANNUALREPORTPURSUANTTOSECTION13OR15。

37、TableofContentsUNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,KANNUALREPORTPURSUANTTOSECTION13OR15。

38、OnMay31,2005,theU,S,FoodandDrugAdministration,FDA,approvedNaglazymeTM,galsulfase,thefirstenzymereplacementtherapyforthet。

39、TableofContentsUNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,KFORANNUALANDTRANSITIONREPORTSPURSUAN。

40、TableofContentsUNITEDSTATESSECURITIESANDE,CHANGECOMMISSIONWASHINGTON,DC20549FORM10,KFORANNUALANDTRANSITIONREPORTSPURSUAN。

【PHARMACEUTICAL】相关PDF文档